These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 22612393)

  • 1. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
    Xu Y; Tong J; Ai Z; Wang J; Teng Y
    J Obstet Gynaecol Res; 2012 Dec; 38(12):1358-66. PubMed ID: 22612393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
    Zhao S; Chen X; Lu X; Yu Y; Feng Y
    Gynecol Oncol; 2007 Apr; 105(1):45-54. PubMed ID: 17240435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway.
    Ai Z; Wang J; Wang Y; Lu L; Tong J; Teng Y
    Cancer; 2010 Aug; 116(15):3603-13. PubMed ID: 20564127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.
    Gu C; Zhang Z; Yu Y; Liu Y; Zhao F; Yin L; Feng Y; Chen X
    Cancer Sci; 2011 Mar; 102(3):557-64. PubMed ID: 21205080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M; He CS; Wei SH; Zhang L
    Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
    Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
    Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.
    Guy MS; Qamar L; Behbakht K; Post MD; Sheeder J; Sartorius CA; Spillman MA
    Gynecol Oncol; 2016 Mar; 140(3):518-26. PubMed ID: 26731726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of long-term treatment with MPA on the biological character of endometrial carcinoma Ishikawa cell].
    Zhao SJ; Chen XJ; Feng YJ
    Fen Zi Xi Bao Sheng Wu Xue Bao; 2007 Apr; 40(2):103-12. PubMed ID: 17580663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RETRACTED: Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
    Morgillo F; D'Aiuto E; Troiani T; Martinelli E; Cascone T; De Palma R; Orditura M; De Vita F; Ciardiello F
    Lung Cancer; 2011 Mar; 71(3):283-90. PubMed ID: 20619923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
    Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
    Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
    Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect and regulation of metformin on endometrial carcinoma subline of progestin-resistance].
    Niu YJ; Shi HR; Xie Y
    Zhonghua Fu Chan Ke Za Zhi; 2016 Feb; 51(2):135-40. PubMed ID: 26917483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-aza-2'-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy.
    Hu Q; Yu L; Chen R; Wang YL; Ji L; Zhang Y; Xie Y; Liao QP
    Int J Gynecol Cancer; 2012 Jul; 22(6):951-9. PubMed ID: 22683940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells.
    Xie Y; Wang YL; Yu L; Hu Q; Ji L; Zhang Y; Liao QP
    J Steroid Biochem Mol Biol; 2011 Sep; 126(3-5):113-20. PubMed ID: 21168492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
    Gendreau SB; Ventura R; Keast P; Laird AD; Yakes FM; Zhang W; Bentzien F; Cancilla B; Lutman J; Chu F; Jackman L; Shi Y; Yu P; Wang J; Aftab DT; Jaeger CT; Meyer SM; De Costa A; Engell K; Chen J; Martini JF; Joly AH
    Clin Cancer Res; 2007 Jun; 13(12):3713-23. PubMed ID: 17575237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.